PDF
(Download)
|
- Aloe (Aloe vera)
- Type 2 Diabetes
- Hypercholesterolemia
- Glycemia
| Date:
05-15-2012 | HC# 041261-448
|
Re: Aloe Gel in the Treatment of Diabetic Hyperlipidemia: More Study Needed
Huseini
HF, Kianbakht S, Hajiaghaee R, Dabaghian FH. Anti-hyperglycemic and
anti-hypercholesterolemic effects of Aloe
vera leaf gel in hyperlipidemic type 2 diabetic patients: a randomized
double-blind placebo-controlled clinical trial. Planta Med. March 2012;78(4):311-316.
Type 2
diabetes mellitus (T2DM) is a prevalent disease worldwide, in part
characterized by elevated low-density lipoprotein (LDL) cholesterol, very
low-density lipoprotein (VLDL) cholesterol, and triglycerides, as well as lower
than normal high-density lipoprotein (HDL) cholesterol. Pharmaceutical agents
used to treat this hyperlipidemic condition in T2DM vary in mechanisms of
action and are typically used concurrently; many are also associated with
adverse side effects. This necessitates the search for broader and safer agents
for both hyperglycemia and hyperlipidemia. Aloe (Aloe vera) has been used traditionally for wound healing and as a
laxative.1 In addition, the acetylated polymannose compound known as
acemannan is thought to largely account for aloe's bioactivity.1
Although many previous studies have shown aloe to be effective in lowering
glucose, lipids, and cholesterol both clinically and in vivo, there is a need
for more rigorous studies with specific endpoints. This randomized,
double-blind, placebo-controlled clinical trial investigates aloe gel for treating hyperlipidemia in T2DM patients.
The aloe was
procured from the Research Institute of Medicinal Plants in Karaj, Iran.
The gel was manually extracted from the inside of a washed aloe leaf. The
bioactive compounds aloin and anthraquinone were removed and the gel was freeze-dried.
The acemannan was quantified using high-performance thin layer chromatography
(HPTLC) with an acemannan standard. Gelatin capsules were filled with 300 mg of
aloe gel powder each or "toast powder" as a placebo. No other
description of the placebo is provided.
Included
patients were Iranian men and women with T2DM who were between 40-60 years of
age. The 3 main criteria were patients with fasting blood glucose
concentrations of 150 mg/dl to 200 mg/dl, hemoglobin A1c (HbA1c) levels from 7-9%,
and who were taking glyburide (10 mg/day) and metformin (1000 mg/day); those
that only took glyburide (10 mg/day) and metformin (1000 mg/day); and patients
recently diagnosed with T2DM that had fasting blood concentrations of LDL cholesterol
and/or triglycerides between 100 mg/dl and 150 mg/dl. Those on other diabetes
pharmaceuticals (including insulin); who had other serious health conditions;
who were using estrogen, steroids, beta-blockers, or thiazide; or who were pregnant,
trying to get pregnant, or breastfeeding were excluded.
A total of 67
patients were randomized to either the aloe (n=33) or placebo group (n=34),
with 7 patients lost to follow-up, resulting in n=30 for each group completing
the study. Patients took either 300 mg of aloe or placebo every 12-hour period
for 2 months. They were also counselled on a healthy diet, kept a food diary
for 3 days of each week, and were asked to return unconsumed capsules at the
end of the study to ensure compliance. The primary endpoints were changes in
fasting blood concentrations of glucose, HbA1c, and lipids, which were taken at
baseline and at the end of the study. Secondary endpoints included fasting
blood concentrations of lipids, bilirubin, blood urea nitrogen, aspartate
aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP),
γ-glutamyl transpeptidase (GGT), and peptidase.
The demographic
data and all blood measures were not significantly different between the aloe
and placebo groups at baseline. There were no adverse effects reported. Patients in the aloe group had lower glucose
concentrations at the end of the study than at baseline; these were
significantly lower than those in the placebo group (167.8 ± 8 mg/dl vs. 191.2
± 42.9 mg/dl, P=0.036). At the end of the study, the aloe group also had
significantly decreased HbA1c concentrations as compared to placebo (6.6 ± 1.1%
vs. 7.8 ± 1.8%, P=0.036). Although the total cholesterol of the aloe group decreased
over the course of the study, it was significantly higher than that of the
placebo group at the end of the study (217.9 ± 28.2 mg/dl vs. 181.0 ± 42.9
mg/dl, P=0.006). No corresponding increase in HDL cholesterol was seen in
either group. Also, the aloe group's LDL cholesterol concentrations were higher
than the placebo group's at the end of the study (125.7 ± 15.2 mg/dl vs. 100.6
± 25.4 mg/dl, P=0.004). None of the other parameters measured were
significantly different, and patients did not report any adverse side effects.
In summary,
this study reports that aloe gel supplements led to decreased blood glucose,
total cholesterol, and LDL cholesterol concentrations, but baseline and
endpoint measurements were not statistically compared. As this would seem an
obvious analysis, omitting this data is unusual and makes assessing the
bioactivity difficult. The results of this study somewhat agree with previous
reports, and discrepancies are thought to be due to a small sample size. One
major problem with this study is the failure to ensure the intake of glyburide
and metformin in all patients. Included patients should be on the same dosage
of both agents in order to assess any drug-herb interaction effects and to standardize
any variation from this; the authors are unclear as to whether this was done. Despite
this, standardizing the aloe gel to acemannan adds rigor to the material used,
and aloe gel is worthy of future clinical trials in T2DM patients.
—Amy C. Keller, PhD
Reference
1Engels G. Aloe. HerbalGram.
2010;(87):1-5.
|